These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30257941)

  • 1. ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis.
    Reese JM; Bruinsma ES; Nelson AW; Chernukhin I; Carroll JS; Li Y; Subramaniam M; Suman VJ; Negron V; Monroe DG; Ingle JN; Goetz MP; Hawse JR
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):E9580-E9589. PubMed ID: 30257941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
    Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
    Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
    Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
    J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen Receptor Beta 1: A Potential Therapeutic Target for Female Triple Negative Breast Cancer.
    Dey P; Wang A; Ziegler Y; Kumar S; Yan S; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
    Endocrinology; 2022 Oct; 163(12):. PubMed ID: 36251879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drivers and suppressors of triple-negative breast cancer.
    Wu W; Warner M; Wang L; He WW; Zhao R; Guan X; Botero C; Huang B; Ion C; Coombes C; Gustafsson JA
    Proc Natl Acad Sci U S A; 2021 Aug; 118(33):. PubMed ID: 34389675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction Proteomics Identifies ERbeta Association with Chromatin Repressive Complexes to Inhibit Cholesterol Biosynthesis and Exert An Oncosuppressive Role in Triple-negative Breast Cancer.
    Alexandrova E; Giurato G; Saggese P; Pecoraro G; Lamberti J; Ravo M; Rizzo F; Rocco D; Tarallo R; Nyman TA; Collina F; Cantile M; Di Bonito M; Botti G; Nassa G; Weisz A
    Mol Cell Proteomics; 2020 Feb; 19(2):245-260. PubMed ID: 31792072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer.
    Alexandrova E; Lamberti J; Saggese P; Pecoraro G; Memoli D; Cappa VM; Ravo M; Iorio R; Tarallo R; Rizzo F; Collina F; Cantile M; Bonito MD; Botti G; Nassa G; Weisz A; Giurato G
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells.
    Shanle EK; Zhao Z; Hawse J; Wisinski K; Keles S; Yuan M; Xu W
    Mol Endocrinol; 2013 Oct; 27(10):1762-75. PubMed ID: 23979844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.
    Yan S; Dey P; Ziegler Y; Jiao X; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
    Breast Cancer Res Treat; 2021 Jan; 185(2):281-292. PubMed ID: 33001337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.
    Schüler-Toprak S; Häring J; Inwald EC; Moehle C; Ortmann O; Treeck O
    BMC Cancer; 2016 Dec; 16(1):951. PubMed ID: 28003019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
    Hinsche O; Girgert R; Emons G; Gründker C
    Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.
    Salahuddin A; Ghanem H; Omran GA; Helmy MW
    Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KiSS1 gene as a novel mediator of TGFβ-mediated cell invasion in triple negative breast cancer.
    Tian J; Al-Odaini AA; Wang Y; Korah J; Dai M; Xiao L; Ali S; Lebrun JJ
    Cell Signal; 2018 Jan; 42():1-10. PubMed ID: 28988968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study.
    Wisinski KB; Xu W; Tevaarwerk AJ; Saha S; Kim K; Traynor A; Dietrich L; Hegeman R; Patel D; Blank J; Harter J; Burkard ME
    Clin Breast Cancer; 2016 Aug; 16(4):256-61. PubMed ID: 27133732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.
    González-González A; Muñoz-Muela E; Marchal JA; Cara FE; Molina MP; Cruz-Lozano M; Jiménez G; Verma A; Ramírez A; Qian W; Chen W; Kozielski AJ; Elemento O; Martín-Salvago MD; Luque RJ; Rosa-Garrido C; Landeira D; Quintana-Romero M; Rosato RR; García MA; Ramirez-Tortosa CL; Kim H; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Lorente JA; Sánchez-Rovira P; Chang JC; Granados-Principal S
    Clin Cancer Res; 2018 Nov; 24(22):5697-5709. PubMed ID: 30012564
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53.
    Scarpetti L; Oturkar CC; Juric D; Shellock M; Malvarosa G; Post K; Isakoff S; Wang N; Nahed B; Oh K; Das GM; Bardia A
    Oncologist; 2023 Apr; 28(4):358-363. PubMed ID: 36772966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.
    Bado I; Nikolos F; Rajapaksa G; Gustafsson JÅ; Thomas C
    Oncotarget; 2016 Mar; 7(12):13599-611. PubMed ID: 26871946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer.
    McNamara KM; Oguro S; Omata F; Kikuchi K; Guestini F; Suzuki K; Yang Y; Abe E; Hirakawa H; Brown KA; Takanori I; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2017 Jan; 161(2):213-227. PubMed ID: 27848152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
    Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
    Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.